When Adjuvant Immunotherapy for Resectable NSCLC May Be the Better Approach

CME credits: 0.50

Valid until: 28-06-2025

Claim your CME credit at https://reachmd.com/programs/cme/when-adjuvant-immunotherapy-for-resectable-nsclc-may-be-the-better-approach/26323/

This educational activity highlights the latest advancements in perioperative immunotherapy for early-stage non-small cell lung cancer and emphasizes the importance of accurate staging, molecular profiling, and a multidisciplinary approach. By integrating recent clinical trial data and expert insights, healthcare professionals will learn to evaluate and apply emerging evidence to optimize individualized treatment strategies. Explore the evolving landscape of neoadjuvant and adjuvant chemoimmunotherapy while gaining critical knowledge to improve patient outcomes through collaborative, evidence-based care.